Trial Profile

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SC 291 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Proof of concept
Acronyms ARDENT
Sponsors Sana Biotechnology

11 Nov 2024 Planned End Date changed from 1 Dec 2027 to 4 Nov 2038.
11 Nov 2024 Planned primary completion date changed from 1 Dec 2026 to 4 Nov 2025.
11 Nov 2024 Status changed from suspended to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com